4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-458246
Co-Chief Executive Officer sold 100,000 shares at an average $29.84 ($2,983,838)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Klee Justin B. Co-Chief Executive Officer | 2026-11-09 | Sale 10b5-1 | −37,483 | $29.39 | $1,101,689 | 3,575,573 | D |
| Klee Justin B. Co-Chief Executive Officer | 2026-11-09 | Sale 10b5-1 | −62,517 | $30.11 | $1,882,149 | 3,513,056 | D |
| Open-market sales · 100,000 sh · avg $29.84 · $2,983,838 | |||||||
Loading xslF345X06/ownership.xml…